Cargando…

KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer

SIMPLE SUMMARY: In this retrospective study including 580 patients with metastatic (Stage IV) non-small cell lung cancer, we investigated whether KRAS mutational status had any impact on clinical outcome. First, we analyzed overall survival of patients grouped based on absence (KRAS(WT)) or presence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eklund, Ella A., Wiel, Clotilde, Fagman, Henrik, Akyürek, Levent M., Raghavan, Sukanya, Nyman, Jan, Hallqvist, Andreas, Sayin, Volkan I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103674/ https://www.ncbi.nlm.nih.gov/pubmed/35565194 http://dx.doi.org/10.3390/cancers14092063

Ejemplares similares

Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer
por: Dutta, Nikita, et al.
Publicado: (2023)

Tissue specificity of oncogenic BRAF targeted to lung and thyroid through a shared lineage factor
por: Schoultz, Elin, et al.
Publicado: (2023)

Immune checkpoint blockade and biomarkers of clinical response in non–small cell lung cancer
por: Hallqvist, Andreas, et al.
Publicado: (2020)

Mitochondria-Targeted Antioxidants MitoQ and MitoTEMPO Do Not Influence BRAF-Driven Malignant Melanoma and KRAS-Driven Lung Cancer Progression in Mice
por: Le Gal, Kristell, et al.
Publicado: (2021)

Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy
por: Hallqvist, A., et al.
Publicado: (2012)

Antioxidants Promote Intestinal Tumor Progression in Mice
por: Zou, Zhiyuan V., et al.
Publicado: (2021)

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

Realities of KRAS-mutated non-small cell lung cancer
por: Min, Young Joo
Publicado: (2017)

A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung Cancer
por: Manolakos, Peter, et al.
Publicado: (2023)

KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma
por: PALIOGIANNIS, PANAGIOTIS, et al.
Publicado: (2014)

The predictive value of KRAS and NRAS mutations in metastatic colorectal cancer
por: Eshraghi, Abbas, et al.
Publicado: (2020)

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
por: Judd, Julia, et al.
Publicado: (2021)

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
por: O’Sullivan, Éabha, et al.
Publicado: (2023)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation
por: Radeczky, Peter, et al.
Publicado: (2021)

Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma
por: Ribeiro, Karen Bento, et al.
Publicado: (2013)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
por: Amram, Marie-Laure, et al.
Publicado: (2017)

Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
por: Ucar, Gokhan, et al.
Publicado: (2020)

MEK inhibition suppresses metastatic progression of KRAS‐mutated gastric cancer
por: Yamasaki, Juntaro, et al.
Publicado: (2022)

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
por: Radanova, Maria, et al.
Publicado: (2023)

KRAS Mutations in Squamous Cell Carcinomas of the Lung
por: Acker, Fabian, et al.
Publicado: (2021)

Spatial heterogeneity of KRAS mutations in colorectal cancers in northern France
por: Turpin, Anthony, et al.
Publicado: (2019)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer
por: Kriegshäuser, Gernot, et al.
Publicado: (2011)

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
por: Kim, Mi-Jung, et al.
Publicado: (2012)

Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate
por: Kordiak, Jacek, et al.
Publicado: (2018)

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
por: Vaclova, Tereza, et al.
Publicado: (2022)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
por: Lavacchi, Daniele, et al.
Publicado: (2022)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
por: Birkeland, E, et al.
Publicado: (2012)

Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer
por: Zocche, David M., et al.
Publicado: (2015)

BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy
por: Li, Zi-Nan, et al.
Publicado: (2020)

KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan
por: Awidi, Muhammad, et al.
Publicado: (2019)

Impact of KRAS Mutation on Survival Outcome of Patients With Metastatic Colorectal Cancer in Jordan
por: Alkader, Mohammad S, et al.
Publicado: (2023)

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
por: Lemstrova, Radmila, et al.
Publicado: (2017)

The Role of KRAS Mutational Analysis to Determine the Site of Origin of Metastatic Carcinoma to the Lung: A Case Report
por: Alkhasawneh, Ahmed N., et al.
Publicado: (2012)

Retrospective Data Analysis of Patients With Metastatic Lung Adenocarcinoma With or Without KRAS-Mutation or TTF1-Expression
por: Moeller, Miriam, et al.
Publicado: (2022)

Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
por: Sun, Jong-Mu, et al.
Publicado: (2013)

Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
por: Reita, Damien, et al.
Publicado: (2022)

Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk
por: Wing, Sam E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pbakfoen5j38f7s0i3ad07a7ml